Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia

被引:615
作者
Soriano, Alex [1 ]
Marco, Francesc [2 ]
Martinez, Jose A. [1 ]
Pisos, Elena [1 ]
Almela, Manel [2 ]
Dimova, Veselka P. [2 ]
Alamo, Dolores [2 ]
Ortega, Mar [1 ]
Lopez, Josefina [1 ]
Mensa, Josep [1 ]
机构
[1] Hosp Clin Barcelona, Dept Infect Dis, E-08036 Barcelona, Spain
[2] Hosp Clin Barcelona, Dept Microbiol, E-08036 Barcelona, Spain
关键词
D O I
10.1086/524667
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Vancomycin treatment failure in methicillin-resistant Staphylococcus aureus (MRSA) bacteremia is not uncommon, even when MRSA is susceptible to vancomycin. The aim of our study was to evaluate whether vancomycin minimum inhibitory concentration has any influence on the mortality associated with MRSA bacteremia. Methods. A total of 414 episodes of MRSA bacteremia were prospectively followed-up from 1991 through 2005. MIC of vancomycin for the first isolate was determined by E-test. Clinical variables recorded were age, comorbidity, prior administration of vancomycin, use of corticosteroids, prognosis of underlying disease, source of bacteremia, the need for mechanical ventilation, shock, and mortality. A "treatment group" variable was created and defined as follows: (1) receipt of empirical vancomycin and an isolate with a vancomycin MIC of 1 mg/mL (38 episodes), (2) receipt of empirical vancomycin and an isolate with a vancomycin MIC of 1.5 mu g/mL (90 episodes), (3) receipt of empirical vancomycin and an isolate with a vancomycin MIC of 2 mu g/mL (40 episodes), and (4) receipt of inappropriate empirical therapy (246 episodes). Univariate and multivariate analyses were performed. Results. Episodes caused by strains with a vancomycin MIC of 2 mu g/mL were independently associated with a lower risk of shock (odds ratio [OR], 0.33; 95% confidence interval [CI], 0.15-0.75). Multivariate analysis selected receipt of empirical vancomycin and an isolate with a vancomycin MIC of 2 mg/mL (OR, 6.39; 95% CI, 1.68-24.3), receipt of inappropriate empirical therapy (OR, 3.62; 95% CI,1.20- 10.9), increasing age (OR, 1.02; 95% CI, 1.00-1.04), use of corticosteroids (OR, 1.85; 95% CI, 1.04-3.29), an ultimately (OR, 10.2; 95% CI, 2.85-36.8) or rapidly (OR, 1.81; 95% CI, 1.06-3.10) fatal underlying disease, high-risk (OR, 3.60; 95% CI, 1.89-6.88) and intermediate-risk (OR, 2.18; 95% CI, 1.17-4.04) sources of bacteremia, and shock (OR, 7.38; 95% CI, 4.11-13.3) as the best predictors of mortality. Conclusions. Mortality associated with MRSA bacteremia was significantly higher when the empirical antibiotic was inappropriate and when vancomycin was empirically used for treatment of infection with strains with a high vancomycin MIC (>1 mu g/mL).
引用
收藏
页码:193 / 200
页数:8
相关论文
共 36 条
[1]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[2]   Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study [J].
Cepeda, JA ;
Whitehouse, T ;
Cooper, B ;
Hails, J ;
Jones, K ;
Kwaku, F ;
Taylor, L ;
Hayman, S ;
Shaw, S ;
Kibbler, C ;
Shulman, R ;
Singer, M ;
Wilson, APR .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (02) :345-355
[3]  
Clinical and Laboratory Standards Institute, 2006, M100S16 CLIN LAB STA
[4]   Novel mechanism of antibiotic resistance originating in vancomycin-intermediate Staphylococcus aureus [J].
Cui, LZ ;
Iwamoto, A ;
Lian, JQ ;
Neoh, HM ;
Maruyama, T ;
Horikawa, Y ;
Hiramatsu, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (02) :428-438
[5]   A mouse peritonitis model for the study of glycopeptide efficacy in GISA infections [J].
Domenech, A ;
Ribes, S ;
Cabellos, C ;
Domínguez, MA ;
Montero, A ;
Liñares, J ;
Ariza, J ;
Gudiol, F .
MICROBIAL DRUG RESISTANCE, 2004, 10 (04) :346-353
[6]   Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus [J].
Fowler, Vance G., Jr. ;
Boucher, Helen W. ;
Corey, G. Ralph ;
Abrutyn, Elias ;
Karchmer, Adolf W. ;
Rupp, Mark E. ;
Levine, Donald P. ;
Chambers, Henry F. ;
Tally, Francis P. ;
Vigliani, Gloria A. ;
Cabell, Christopher H. ;
Link, Arthur Stanley ;
DeMeyer, Ignace ;
Filler, Scott G. ;
Zervos, Marcus ;
Cook, Paul ;
Parsonnet, Jeffrey ;
Bernstein, Jack M. ;
Price, Connie Savor ;
Forrest, Graeme N. ;
Faetkenheuer, Gerd ;
Gareca, Marcelo ;
Rehm, Susan J. ;
Brodt, Hans Reinhardt ;
Tice, Alan ;
Cosgrove, Sara E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (07) :653-665
[7]   Epidemiological and microbiological characterization of infections caused by Staphylococcus aureus with reduced susceptibility to vancomycin, United States, 1997-2001 [J].
Fridkin, SK ;
Hageman, J ;
McDougal, LK ;
Mohammed, J ;
Jarvis, WR ;
Perl, TM ;
Tenover, FC .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (04) :429-439
[8]   CDC DEFINITIONS FOR NOSOCOMIAL INFECTIONS, 1988 [J].
GARNER, JS ;
JARVIS, WR ;
EMORI, TG ;
HORAN, TC ;
HUGHES, JM .
AMERICAN JOURNAL OF INFECTION CONTROL, 1988, 16 (03) :128-140
[9]   High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections -: Efficacy and toxicity [J].
Hidayat, Levita K. ;
Hsu, Donald I. ;
Quist, Ryan ;
Shriner, Kimberly A. ;
Wong-Beringer, Annie .
ARCHIVES OF INTERNAL MEDICINE, 2006, 166 (19) :2138-2144
[10]   Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility [J].
Howden, BP ;
Ward, PB ;
Charles, PGP ;
Korman, TM ;
Fuller, A ;
du Cros, P ;
Grabsch, EA ;
Roberts, SA ;
Robson, J ;
Read, K ;
Bak, N ;
Hurley, J ;
Johnson, PDR ;
Morris, AJ ;
Mayall, BC ;
Grayson, ML .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (04) :521-528